PCSK9抑制剂和骨质疏松症:孟德尔的随机化和元分析
Ding-Qiang Chen1,2, Wen-Bin Xu3, Ke-Yi Xiao1,2
1Department of Orthopedics, The First Affiliated Hospital of Xiamen University, Xiamen, China.
BMC musculoskeletal disorders
|July 15, 2024
概括
根据孟德尔的随机化分析,蛋白转化酶子素/素9型 (PCSK9) 抑制剂可能会增加骨质疏松症的风险. 然而,3-基-3-甲基氨酸共因子A减少酶 (HMGCR) 抑制剂与骨密度变化没有关联.
科学领域:
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 抑制剂是有效的心血管疾病风险降低剂.
- 对于PCSK9抑制的骨效应尚不清楚.
- 门德尔随机化 (MR) 是研究药物标因果关系的一个有价值的工具.
研究的目的:
- 研究PCSK9抑制对骨质疏松症风险的潜在因果作用.
- 研究HMGCR抑制剂与骨质疏松症风险之间的关联.
主要方法:
- 从欧洲人群中的HMGCR和PCSK9遗传数据中利用单核酸多态 (SNPs).
- 使用全基因组关联研究 (GWAS) 数据对骨质疏松症和冠状动脉疾病 (CAD) 进行孟德尔随机化分析.
- 进行敏感性分析和元分析以评估因果关系并确认发现.
主要成果:
- 一项对1,263,102个人的元分析表明,PCSK9抑制剂与骨质疏松症的风险增加有关 (P <0.05).
- HMGCR 抑制剂与骨质疏松症风险没有显著关联.
- 使用独立GWAS数据集的复制分析得出了一致的结论.
结论:
- 抑制PCSK9与患骨质疏松症的风险增加有关.
- HMGCR 抑制剂似乎没有影响骨质疏松症风险.
更多相关视频
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
13.3K
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.4K
相关概念视频
Osteoclasts in Bone Remodeling
2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
